載入...
SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
Globally, diabetes mellitus is a leading cause of kidney disease, with a critical percent of patients approaching end-stage kidney disease. In the current era, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as phenomenal agents in halting the progression of kidney disease. Positive...
Na minha lista:
| 發表在: | J Clin Med |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
MDPI
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7564486/ https://ncbi.nlm.nih.gov/pubmed/32846935 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9092723 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|